Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15679557 | 0.89 | CYP3A4 (0.46) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL19978992 | 0.88 | CYP3A4 (0.37) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL18914515 | 0.88 | TSHR (0.35) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL19978993 | 0.88 | USP2 (0.32) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL18390364 | 0.88 | USP2 (0.39) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL19704965 | 0.85 | TSHR (0.36) | CYP3A4CYP2D6CYP1A2TSHRDRD4 | |
| SCHEMBL20218197 | 0.85 | USP2 (0.32) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL19979493 | 0.84 | — | — | |
| SCHEMBL1753720 | 0.84 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP1A2TSHRUSP2 | |
| SCHEMBL19264173 | 0.82 | USP2 (0.43) | CYP3A4CYP2D6CYP1A2TSHRUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEONE MEDICINES I GMBH (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-3337460-B1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-15 | — | — | EP | disclosed |
| EP-3337477-B1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | CONVALIFE SHANGHAI CO LTD (CN) | 2023-02-01 | — | — | EP | disclosed |
| WO-2022127847-A1 | PYRIMIDONE DERIVATIVE AND APPLICATION THEREOF IN DRUG | 广东东阳光药业有限公司 | 2022-06-23 | — | — | WO | disclosed |
| EP-3512857-B1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3145929-B1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS WHICH ARE JAK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-13 | — | — | EP | disclosed |
| WO-2020200069-A1 | PYRROLOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2020-10-08 | — | — | WO | disclosed |
| EP-3456355-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | Karus Therapeutics Ltd (GB) | 2019-03-20 | — | — | EP | disclosed |
| EP-2980087-B1 | PRODRUGS OF BICYCLIC SUBSTITUTED PYRIMIDINE TYPE PDE-5 INHIBITORS | XUANZHU PHARMA CO LTD (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-3105233-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | KARUS THERAPEUTICS LTD (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2018050686-A1 | SPIRO BICYCLIC INHIBITORS OF MENIN-MLL INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-22 | — | — | WO | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| WO-2017029517-A1 | COMPOSITIONS COMPRISING PHOSPHOINOSITIDE 3-KINASE INHIBITORS AND A SECOND ANTIPROLIFERATIVE AGENT | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029514-A1 | COMPOSITIONS COMPRISING A PI3K INHIBITOR AND AN HDAC INHIBITOR | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029518-A1 | COMPOSITIONS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS | KARUS THERAPEUTICS LTD (GB) | 2017-02-23 | — | — | WO | disclosed |
| EP-1802636-B1 | PI3 KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2013-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265116-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CYP3A4 4575/4885CYP2D6 4546/4885CYP1A2 4616/4885 |
| US-20230248834-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | EGFR, CBL, ERBB2 | CYP3A4 4575/4885CYP2D6 4546/4885CYP1A2 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.